

Todd C Skaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4238835/publications.pdf>

Version: 2024-02-01

141
papers

6,782
citations

87888

38
h-index

64796

79
g-index

144
all docs

144
docs citations

144
times ranked

7354
citing authors

#	ARTICLE	IF	CITATIONS
1	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. <i>Clinical and Translational Science</i> , 2022, 15, 371-383.	3.1	13
2	<i>CYP2C19</i> Genotypeâ€œGuided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. <i>Journal of the American Heart Association</i> , 2022, 11, e024159.	3.7	24
3	Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100312.	3.0	9
4	Abstract P1-08-02: Cytochrome P450 reductase gene<i>, POR,</i> associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103. <i>Cancer Research</i> , 2022, 82, P1-08-02-P1-08-02.	0.9	1
5	eP373: Analytical validation of a computational method for pharmacogenetic genotyping from clinical exome sequencing. <i>Genetics in Medicine</i> , 2022, 24, S234-S235.	2.4	0
6	Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. <i>Kidney360</i> , 2022, 3, 307-316.	2.1	9
7	Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 576-585.	2.8	7
8	A pilot study of <i>ADRA2A</i> genotype association with doses of dexmedetomidine for sedation in pediatric patients. <i>Pharmacotherapy</i> , 2022, . .	2.6	1
9	Bestâ€œworst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. <i>Implementation Science Communications</i> , 2022, 3, 52.	2.2	4
10	The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e33.	0.6	0
11	Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 485-493.	4.7	2
12	Tracheal Aspirate as an Alternative Biologic Sample for Pharmacogenomics Testing in Mechanically Ventilated Pediatric Patients. <i>Clinical and Translational Science</i> , 2021, 14, 497-501.	3.1	1
13	Variability of Dosing and Number of Medications Needed to Achieve Adequate Sedation in Mechanically Ventilated Pediatric Intensive Care Patients. <i>Clinical and Translational Science</i> , 2021, 14, 310-316.	3.1	4
14	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotypeâ€œGuided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	4.7	25
15	Allele-specific expression and high-throughput reporter assay reveal functional genetic variants associated with alcohol use disorders. <i>Molecular Psychiatry</i> , 2021, 26, 1142-1151.	7.9	26
16	Opportunity for Genotypeâ€œGuided Prescribing Among Adult Patients in 11 US Health Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 179-188.	4.7	35
17	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i>, <i>OPRM1</i>, and <i>COMT</i> Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 888-896.	4.7	212
18	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. <i>Genetics in Medicine</i> , 2021, 23, 1185-1191.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Ending the pharmacogenomic gag rule: the imperative to report all results. <i>Pharmacogenomics</i> , 2021, 22, 191-193.	1.3	2
20	Prevalence of the concurrent administration of contraindicated medications in patients with cancer treated with tyrosine kinase inhibitors (TKIs): A pilot study from the IU Simon Comprehensive Cancer Center. <i>Journal of Clinical Oncology</i> , 2021, 39, e18714-e18714.	1.6	0
21	Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. <i>Journal of Clinical Oncology</i> , 2021, 39, 12003-12003.	1.6	1
22	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 116-123.	1.5	4
23	Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. <i>Journal of Personalized Medicine</i> , 2021, 11, 647.	2.5	13
24	Mapping the miRNA-mRNA Interactome in Human Hepatocytes and Identification of Functional mirSNPs in Pharmacogenes. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1106-1118.	4.7	9
25	Opportunity for pharmacogenomic testing in patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2021, , .	2.0	6
26	Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 809527.	2.8	7
27	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 50-52.	4.7	22
28	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. <i>Genetics in Medicine</i> , 2020, 22, 1898-1902.	2.4	9
29	Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2155-2162.	4.1	4
30	Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers. <i>Drug Metabolism and Disposition</i> , 2020, 48, 169-175.	3.3	4
31	Severe Capecitabine Toxicity Associated With a Rare <i>DPYD</i> Variant Identified Through Whole-Genome Sequencing. <i>JCO Precision Oncology</i> , 2020, 4, 632-638.	3.0	9
32	Enrollment of Diverse Populations in the INGENIOUS Pharmacogenetics Clinical Trial. <i>Frontiers in Genetics</i> , 2020, 11, 571.	2.3	8
33	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , 2020, 20, 724-735.	2.0	25
34	Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance. <i>Life</i> , 2020, 10, 32.	2.4	11
35	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. <i>JAMA Network Open</i> , 2020, 3, e2029411.	5.9	34
36	Genome-wide association study of steady-state letrozole concentration in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 538-538.	1.6	14

#	ARTICLE	IF	CITATIONS
37	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. <i>Pharmacogenomics</i> , 2019, 20, 571-580.	1.3	7
38	MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 433-442.	2.0	30
39	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. <i>Genetics in Medicine</i> , 2019, 21, 2255-2263.	2.4	53
40	Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. <i>Pharmacogenomics</i> , 2019, 20, 397-408.	1.3	15
41	Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 491-502.	2.8	1
42	RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants. <i>Genome Biology</i> , 2019, 20, 254.	8.8	52
43	Qualitative study of system-level factors related to genomic implementation. <i>Genetics in Medicine</i> , 2019, 21, 1534-1540.	2.4	26
44	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	4.7	110
45	CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 755-757.	4.7	2
46	Rifampin modulation of xenobiotic and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00386.	2.4	18
47	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674.	4.7	94
48	Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. <i>Nature Communications</i> , 2018, 9, 828.	12.8	67
49	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	2.9	213
50	Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 130-138.	4.7	21
51	Next generation MicroRNA sequencing to identify coronary artery disease patients at risk of recurrent myocardial infarction. <i>Atherosclerosis</i> , 2018, 278, 232-239.	0.8	26
52	Report of Confirmation of the rs7853758 and rs885004 Haplotype in SLC28A3. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 652-655.	0.7	2
53	PASSPORT-seq: A Novel High-Throughput Bioassay to Functionally Test Polymorphisms in Micro-RNA Target Sites. <i>Frontiers in Genetics</i> , 2018, 9, 219.	2.3	9
54	Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-543.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson. <i>Pharmacogenomics</i> , 2017, 18, 523-529.	1.3	2
56	Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1497-1504.	2.6	39
57	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 453-461.	2.5	8
58	CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. <i>Applied Nursing Research</i> , 2017, 38, 107-110.	2.2	17
59	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 659-668.	2.5	7
60	Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	20
61	Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. <i>International Journal of Molecular Sciences</i> , 2017, 18, 661.	4.1	2
62	<i>In Vivo</i> siRNA Delivery and Rebound of Renal LRP2 in Mice. <i>Journal of Drug Delivery</i> , 2017, 2017, 1-12.	2.5	7
63	Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1063-1063.	1.6	1
64	Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 145-145.	1.6	0
65	Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. <i>Oncotarget</i> , 2016, 7, 56491-56500.	1.8	75
66	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. <i>Frontiers in Pharmacology</i> , 2016, 7, 111.	3.5	32
67	ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. <i>Physiological Genomics</i> , 2016, 48, 688-698.	2.3	9
68	A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors $\hat{1}\pm$ and $\hat{1}^2$. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5400-5409.	3.0	16
69	Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6813-6822.	3.2	8
70	Identification of rifampin-regulated functional modules and related microRNAs in human hepatocytes based on the protein interaction network. <i>BMC Genomics</i> , 2016, 17, 517.	2.8	6
71	Sleep disorders in breast cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 4197-4205.	2.2	34
72	Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. <i>Oncologist</i> , 2016, 21, 539-546.	3.7	56

#	ARTICLE	IF	CITATIONS
73	Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 157-170.	6.4	23
74	Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1395-1402.	7.0	18
75	Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 107-116.	2.2	14
76	A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. <i>Journal of Clinical Oncology</i> , 2016, 34, 546-546.	1.6	2
77	Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. <i>Clinical Interventions in Aging</i> , 2015, 10, 269.	2.9	9
78	Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 205-215.	4.7	36
79	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2015, 126, 413-422.	2.4	47
80	FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 725-727.	2.0	6
81	Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2623-2648.	6.4	33
82	<i>AMPD1</i> polymorphism and response to regadenoson. <i>Pharmacogenomics</i> , 2015, 16, 1807-1815.	1.3	2
83	Report of New Haplotype for <i>ABCC2</i> Gene. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 201-205.	2.8	3
84	Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained?. <i>Cancer Medicine</i> , 2015, 4, 183-200.	2.8	109
85	Cypiripi: exact genotyping of <i>CYP2D6</i> using high-throughput sequencing data. <i>Bioinformatics</i> , 2015, 31, i27-i34.	4.1	37
86	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , 2015, 9, 1868-1876.	4.6	29
87	A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 72-76.	0.6	3
88	Considerations for the Utility of the CPIC Guideline for <i>CYP2D6</i> Genotype and Codeine Therapy. <i>Clinical Chemistry</i> , 2015, 61, 775-776.	3.2	13
89	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 263-273.	2.5	27
90	Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0141279.	2.5	49

#	ARTICLE	IF	CITATIONS
91	Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses.. Journal of Clinical Oncology, 2015, 33, 1528-1528.	1.6	1
92	Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements. PLoS Genetics, 2014, 10, e1004648.	3.5	36
93	Medication use in breast cancer survivors compared to midlife women. Supportive Care in Cancer, 2013, 21, 1827-1833.	2.2	3
94	Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal of the National Cancer Institute, 2013, 105, 1332-1334.	6.3	33
95	Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Research and Treatment, 2013, 138, 807-816.	2.5	50
96	Incubation of Whole Blood at Room Temperature Does Not Alter the Plasma Concentrations of MicroRNA-16 and -223. Drug Metabolism and Disposition, 2013, 41, 1778-1781.	3.3	22
97	Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes. Drug Metabolism and Disposition, 2013, 41, 1763-1768.	3.3	33
98	Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3207-3215.	3.6	26
99	Evaluating the Role of Serotonin on Neuropsychological Function After Breast Cancer Using Acute Tryptophan Depletion. Biological Research for Nursing, 2012, 14, 5-15.	1.9	3
100	In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4 β Expression. Drug Metabolism and Disposition, 2012, 40, 726-733.	3.3	79
101	Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes. Frontiers in Pharmacology, 2012, 3, 54.	3.5	1
102	Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene. Hormones and Cancer, 2012, 3, 37-43.	4.9	16
103	Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy.. Journal of Clinical Oncology, 2012, 30, 525-525.	1.6	57
104	In Silico Identification of MicroRNAs Predicted to Regulate the Drug Metabolizing Cytochrome P450 Genes. Drug Metabolism Letters, 2011, 5, 126-131.	0.8	38
105	Human Breast Milk as a Source of DNA for Amplification. Journal of Clinical Pharmacology, 2011, 51, 616-619.	2.0	9
106	Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole. Cancer Prevention Research, 2011, 4, 1993-2001.	1.5	23
107	Gene copy number variations: it is important to determine which allele is affected. Pharmacogenomics, 2011, 12, 299-301.	1.3	24
108	Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity. Angiogenesis, 2010, 13, 211-218.	7.2	11

#	ARTICLE	IF	CITATIONS
109	Significant Effect of Polymorphisms in <i>CYP2D6</i> and <i>ABCC2</i> on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 1287-1293.	1.6	214
110	Composite Functional Genetic and Comedication <i>CYP2D6</i> Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 450-458.	2.0	102
111	Differential quantification of <i>CYP2D6</i> gene copy number by four different quantitative real-time PCR assays. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 451-454.	1.5	34
112	Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 543-549.	2.5	11
113	Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 643-650.	2.5	37
114	Association between <i>CYP2D6</i> genotype and tamoxifen-induced hot flashes in a prospective cohort. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 571-575.	2.5	63
115	Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. <i>Journal of Immunology</i> , 2009, 182, 216-24.	0.8	52
116	Association of polymorphisms of angiogenesis genes with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 157-163.	2.5	108
117	Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5849-5854.	1.6	49
118	A Mixture Model Approach in Gene-Gene and Gene-Environmental Interactions for Binary Phenotypes. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 1150-1177.	0.8	6
119	MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma. <i>Journal of Immunology</i> , 2008, 181, 3116-3125.	0.8	99
120	The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 61-64.	1.0	17
121	Quantitative effect of <i>CYP2D6</i> genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 61-74.	4.7	424
122	Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 209-215.	2.5	27
123	Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 503-512.	2.5	127
124	Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 178-188.	4.7	60
125	Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 471-478.	2.3	260
126	<i>CYP2D6</i> Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 30-39.	6.3	867

#	ARTICLE	IF	CITATIONS
127	Association Between the CYP3A5 Genotype and Blood Pressure. <i>Hypertension</i> , 2005, 45, 294-298.	2.7	79
128	Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. <i>Carcinogenesis</i> , 2005, 26, 1527-1535.	2.8	125
129	Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant). <i>Cancer Research</i> , 2004, 64, 4030-4039.	0.9	63
130	Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2004, 85, 151-159.	2.5	418
131	Functional characterization of the 5' regulatory region of human CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, P60-P60.	4.7	0
132	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. <i>Oncogene</i> , 2003, 22, 7316-7339.	5.9	421
133	Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). <i>Cancer Research</i> , 2002, 62, 3428-37.	0.9	80
134	Molecular and pharmacological aspects of antiestrogen resistance. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 76, 71-84.	2.5	125
135	Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cells in Vitro and in Vivo*. <i>Endocrinology</i> , 2001, 142, 1497-1505.	2.8	34
136	Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cells in Vitro and in Vivo. <i>Endocrinology</i> , 2001, 142, 1497-1505.	2.8	18
137	Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 67, 391-402.	2.5	65
138	Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. <i>Breast Cancer Research and Treatment</i> , 1994, 31, 237-248.	2.5	60
139	Regulation of Insulin-like Growth Factor Binding Protein Secretion by a Murine Mammary Epithelial Cell Line. <i>Experimental Cell Research</i> , 1993, 209, 183-188.	2.6	20
140	Seasonal Effects of Prepartum and Postpartum Fat and Niacin Feeding on Lactation Performance and Lipid Metabolism. <i>Journal of Dairy Science</i> , 1989, 72, 2028-2038.	3.4	125
141	Medication Exposure Patterns in Primary Care Patients Prescribed Pharmacogenetically Actionable Opioids. <i>Qualitative Report</i> , 0, , .	0.1	0